Horwitz, S. M., Foran, J. M., Maris, M., Lue, J. K., Sawas, A., Okada, C., Feldman, T. A., Sokol, L., Mei, M., Flinn, I. W., Villa, D., Percival, M.-E. M., Jagadeesh, D., Savage, K. J., Akilov, O., Diefenbach, C. S., Kim, Y. H., Lin, G. H. Y., Catalano, T., … Ansell, S. M. (2021). Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies. Blood, 138(Supplement 1), 2448–2448. https://doi.org/10.1182/blood-2021-154490